Telmisartan - Killing two birds with one stone

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2397-2400

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

Animal model of insulin resistance; Diabetes; Hypertension; Irbesartan; PPAR ; PPAR agonism; Telmisartan

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; GLUCOSE; INSULIN; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PYRUVATE KINASE; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

3T3-L1 CELLS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MICE; PPAR GAMMA; RATS; RATS, ZUCKER; TETRAZOLES;

EID: 8544251308     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2397     Document Type: Review

References (12)

1. SCHUPP M, JANKE J, CLASEN R, UNGER T, KINTSCHER U: Angiotensin Type 1 receptor blockers induce peroxisome proliferators-activated receptor-gamma activity. Circulation (2004) 109:2054-2057.
2. BENSON SC, PERSHADSINGH HA, HO CI et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension (2004) 43:993-1002.
3. VIJAN S, HAYWARD RA: Treatment of hypertension in Type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann. Intern. Med. (2003) 138 593-602.
4. DOGGRELL SA: Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin. Pharmacother. (2002) 3:1543-1556.
5. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J. Hypertens. (1999) 17:293-302.
6. MALLION J, SICHE J, LACOURCIERE Y: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J. Hum. Hypertens. (1999) 13:657-664.
7. HENRIKSEN JC, JACOB S, KINNICK TR, TEACHEY MK, KREKLER M: Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension (2001) 38:884-890.
8. WANG CH, LEUNG N, LAPOINTE N et al.: Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II Type I receptor blocker. Circulation (2003) 107:1923-1929.
9. 1 antagonists in Type 2 diabetes with nephropathy. Expert Opin. Pharmacother. (2002) 3 625-628.
10. VIRBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 106:672-678.
11. ROSSING K, CHRISTENSIN PK, HANSEN BV, CARSTENSEN B, PARVING HH: Optimal dose of candesartan for renoprotection in Type 2 patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care (2003) 26:150-155.
12. RIPPIN J, BAIN SC, BARNETT AH: Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J. Diabetic Complications (2002) 16:195-200.